Aspire Biopharma Holdings (ASBP) Cash & Equivalents (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has 5 years of Cash & Equivalents data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 35.66% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 35.66% increase from a year earlier, with the FY2024 full-year figure at $3633.0, down 67.49% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.8 million, up from $1.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ASBP reached as high as $1.8 million in Q1 2026 and fell as low as $3633.0 in Q4 2024.
• Historically, Cash & Equivalents has averaged $484578.2 across 5 years, with a median of $406205.5 in 2022.
• Across the five-year window, Cash & Equivalents slumped 97.75% in 2023 and soared 2747.6% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $497259.0 in 2022, then slumped by 97.75% to $11174.0 in 2023, then tumbled by 67.49% to $3633.0 in 2024, then surged by 36964.22% to $1.3 million in 2025, then surged by 35.66% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.8 million in Q1 2026, $1.3 million in Q1 2025, and $3633.0 in Q4 2024.